Li, Z., Ye, J., Liu, Y., Yao, K., Wu, Z., Ye, Y., Li, X., Zhou, F., Ma, Z., He, L., Liu, Z. (2026). Final results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for high-risk non–muscle-invasive bladder cancer patients unresponsive to Bacillus Calmette-Guerin.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4599